AllSci News
Pfizer joins Swiss biotech accelerator BaseLaunch
Pfizer reportedly joined BaseLaunch, a Basel-based biotech venture incubator and accelerator, as its seventh global pharmaceutical partner. This partnership grants Pfizer strategic…
Galecto makes secondary offering for USD 27.5m
Denmark-based Galecto, Inc. (Nasdaq: GLTO) announced the pricing of an underwritten public offering with total gross proceeds of USD 27.5 million. The…
Moderna receives Refusal-to-File letter from FDA for mRNA flu vaccine mRNA-1010
Moderna gave notice that the US FDA’s Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for its investigational seasonal…
Leqembi subcutaneous formulation secures Priority Review for Alzheimer’s in China
Eisai and Biogen received a priority review award from China’s National Medical Products Administration (NMPA) for the subcutaneous formulation of Leqembi (lecanemab).…
Akeso moves first-in-class IL-4Rα/ST2 BsAb into Phase II for respiratory, autoimmune diseases
China-based Akeso Inc., (9926.HK) announced clearance from China’s National Medical Products Administration (NMPA) to initiate seven Phase II studies for its first-in-class…
Upstream Bio’s long-acting TSLP antibody set for Phase III after positive severe asthma trial
Upstream Bio announced positive top-line results from its Phase II VALIANT clinical trial evaluating verekitug asthma treatment, demonstrating statistically significant reductions in…
Pertussis vaccines firm ILiAD raises USD 115m in Series B
Weston, Florida-based ILiAD Biotechnologies, a clinical-stage biotechnology company focused on the prevention and treatment of diseases caused by Bordetella pertussis, has entered…
ProMIS Neurosciences raises USD 175m in private placement financing
ProMIS Neurosciences (Nasdaq: PMN) announced a private placement in public equity (PIPE) financing of up to approximately USD 175 million before fees…
Moderna finds partners in Mexico to boost mRNA vaccine supply
Moderna Inc., (NASDAQ: MRNA) signed a Memorandum of Understanding (MoU) for a five-year strategic agreement with the Government of Mexico, state-owned Laboratorios…
Roche’s fenebrutinib on par with Ocrevus for multiple sclerosis
Switzerland-based Roche announced positive late-breaking Phase III results from the FENtrepid study evaluating fenebrutinib in patients with primary progressive multiple sclerosis (PPMS).…
Galux secures USD 29m Series B to advance AI-driven protein therapeutics platform
South Korea-based biotechnology firm Galux, which focuses on de novo protein design for drug discovery, has completed a Series B financing round…
MerryLife Biomedical’s TML-6 shows promise in Phase I Alzheimer’s trial
Taiwan-based MerryLife Biomedical announced positive Phase I results for TML-6, an innovative oral Alzheimer’s therapy designed to target multiple neurological pathways simultaneously.…
Kailera, Hengrui to advance oral GLP-1/GIP drug ribupatide after showing 12.1% weight loss
Kailera Therapeutics and China-based Hengrui Pharma announced positive topline data from a Phase II trial for ribupatide in obesity, demonstrating significant weight…
Regenxbio’s Hunter syndrome drug met with FDA CRL
Regenxbio Inc., a Maryland-based biotechnology company, announced that the US FDA has issued a Complete Response Letter (CRL) regarding the Biologics License…
Adlai Nortye backed with USD 140m in strategic financing
Adlai Nortye Ltd. (Nasdaq: ANL), a clinical-stage biotech developing next-generation cancer immunotherapies and RAS-targeting therapies, entered into securities purchase agreements for a…
The AllSci Brief
Systematic R&D and deal news. Daily.